If Novartis does snap up Amneal to beef up its own Sandoz unit, the deal will say as much about the state of the under-pressure generics industry as it does…

As execs admit Alcon might not fit Novartis' long-term plans, the Swiss drugmaker has found a short-term boost for its Sandoz business: It's in talks…

Word is Pfizer is considering selling or spinning off its consumer health operations and that it could bring in $14 billion or more.

Seeking to overcome a wave of public and governmental attention to its EpiPen, Mylan is working to finalize its $465 million settlement with the federal…

Another quarter, another slump for Gilead’s hepatitis C franchise, with sales down 31%. Despite better-than-expected overall revenue, market-watchers zeroed on…

Earlier this year, Valeant reportedly turned down a takeover offer from Takeda and TPG. Now, the Japanese drugmaker wants to snag just one piece of the…

Biosimilars seem to be all the rage these days--but one pharma player may want out.

After missing out on a much-desired Medivation buy, Sanofi CEO Olivier Brandicourt told analysts Friday that he's still shopping for M&A, and not just…

M&A